1-allyl-1,3,3a,4,5,6,6a,12a-octahydro-7,13-dioxo-1,5-methano-furo[3,4-d]xanthene | 786705-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-allyl-1,3,3a,4,5,6,6a,12a-octahydro-7,13-dioxo-1,5-methano-furo[3,4-d]xanthene
• 英文别名: 15-prop-2-enyl-3,16-dioxapentacyclo[11.4.1.02,11.02,15.04,9]octadeca-4,6,8-triene-10,14-dione
• CAS: 786705-90-6
• 化学式: C₁₉H₁₈O₄
• 分子量: 310.35
• InChiKey: ZZDPKFBTCCLAGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-allyl-1,3,3a,4,5,12a-hexahydro-7,13-dioxo-1,5-methano-furo[3,4-d]xanthene 在 L-Selectride 作用下， 以 四氢呋喃 、 二氧化碳 为溶剂， 以11.4 mg (39%)的产率得到1-allyl-1,3,3a,4,5,6,6a,12a-octahydro-7,13-dioxo-1,5-methano-furo[3,4-d]xanthene
  参考文献：
  名称：

  Methods of treating diseases responsive to induction of Apoptosis and screening assays

  摘要：

  本发明涉及一种治疗、预防或改善动物中对caspase级联诱导敏感的疾病的方法，包括向动物中注射一种与一种或多种凋亡诱导蛋白（AIPs）特异结合的化合物。AIPs包括转铁蛋白受体相关凋亡诱导蛋白（TRRAIPs）、衣蛋白重链相关凋亡诱导蛋白（CHCRAIPs）、IQ基序含有GTP酶激活蛋白相关凋亡诱导蛋白（IQGAPRAIPs）和热休克蛋白相关凋亡诱导蛋白（HSPRAIPs）。本发明还涉及用于药物发现凋亡诱导化合物的筛选方法。特别地，筛选方法涉及使用AIPs作为发现凋亡激活剂用于抗癌药物的靶点。本发明的筛选方法可以使用纯化或部分纯化的AIPs进行同质或异质结合分析的细胞分析，或使用具有改变一种或多种AIPs水平的细胞进行整个细胞分析。本发明还考虑使用结合AIPs的苦参酸或GA相关化合物，可用于制备用于药物发现的抗体。或者，标记的GA可用于竞争性结合分析，用于药物发现。这种分析可用于高通量筛选化学库以寻找凋亡激活剂。

  公开号：

  US20050004026A1

文献信息

• Methods of treating diseases responsive to induction of apoptosis and screening assays
  申请人：Cytovia, Inc.

  公开号：US07592143B2

  公开（公告）日：2009-09-22

  The present invention relates to screening methods useful for drug discovery of apoptosis inducing compounds. In particular, the screening methodology relates to using Apoptosis Inducing Proteins (AIPs) as a target for the discovery of apoptosis activators useful as anticancer agents. The screening methods of the present invention can employ homogenous or heterogeneous binding assays using purified or partially purified AIPs; or whole cell assays using cells with altered levels of one or more AIPs. The invention also contemplates use of gambogic acid or GA-related compounds which bind AIPs and can accordingly be used to raise antibodies useful for drug discovery. Alternatively, labeled GA is used for competitive binding assays for drug discovery. Such assays afford high throughput screening of chemical libraries for apoptosis activators.

  本发明涉及用于筛选药物发现的凋亡诱导化合物的筛选方法。特别是，筛选方法涉及使用凋亡诱导蛋白（AIPs）作为靶点，以发现作为抗癌剂有用的凋亡激活剂。本发明的筛选方法可以采用纯化或部分纯化的AIPs的均质或非均质结合测定；或者使用具有一个或多个AIPs水平改变的细胞的全细胞测定。本发明还考虑使用结合AIPs的甘波酸或GA相关化合物，可以用于制备有用于药物发现的抗体。或者，标记的GA用于竞争性结合测定以进行药物发现。这些测定提供了化学库的高通量筛选，以寻找凋亡激活剂。
• METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS
  申请人：Cytovia, Inc.

  公开号：EP1620564A2

  公开（公告）日：2006-02-01
• EP1620564A4
  申请人：——

  公开号：EP1620564A4

  公开（公告）日：2008-03-12
• US7592143B2
  申请人：——

  公开号：US7592143B2

  公开（公告）日：2009-09-22
• [EN] METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS<br/>[FR] PROCEDES POUR TRAITER DES MALADIES ENTRAINANT L'INDUCTION D'APOPTOSE ET ESSAIS DE CRIBLAGE
  申请人：CYTOVIA INC

  公开号：WO2004094647A2

  公开（公告）日：2004-11-04

  The present invention pertains to a method of treating, preventing or ameliorating a disease responsive to induction of the caspase cascade in an animal, comprising administering to the animal a compound which binds specifically to one or more Apoptosis Inducing Proteins (AIPs). AIPs include Transferrin Receptor Related Apoptosis Inducing Proteins (TRRAIPs), Clathrin Heavy Chain Related Apoptosis Inducing Proteins (CHCRAIPs), IQ motif containing GTPase Activating Protein Related Apoptosis Inducing Proteins (IQGAPRAIPs), and Heat Shock Protein Related Apoptosis Inducing Proteins (HSPRAIPs). The present invention also relates to screening methods useful for drug discovery of apoptosis inducing compounds. In particular, the screening methodology relates to using AIPs as a target for the discovery of apoptosis activators useful as anticancer agents. The screening methods of the present invention can employ homogenous or heterogenous binding assays using purified or partially purified AIPs; or whole cell assays using cells with altered levels of one or more AIPs. The invention also contemplates use of gambogic acid or GA-related compounds which bind AIPs and can accordingly be used to raise antibodies useful for drug discovery. Alternatively, labeled GA is used for competitive binding assays for drug discovery. Such assays afford high throughput screening of chemical libraries for apoptosis activators.